Výsledky vyhledávání

AB1417-HPR RHEUMATOLOGY NURSE PRACTICE: EDUCATION TO IMPROVE THE UNDERSTANDING OF RHEUMATIC DISEASES

Autor: Scott Kober, Monica Richey, Carrie Beach, Iris Zink, Sheree Carter, Vickie Sayles, Jacqueline Fritz, Eileen J. Lydon, Cathy Patty-Resk, Linda L Grinnell-Merrick, Elizabeth Kirchner, Eileen Mccullagh

Publikováno v: HPR Professional education, training and competencies.

Background Rheumatology Nurse Practice is an accredited educational initiative spearheaded by members of the Rheumatology Nurses Societys Board of Directors and Education Department that has been ongoing for the last 10 years. It involves a combinati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b03ecd67a26d4432b4f6a087eb1dd25
https://doi.org/10.1136/annrheumdis-2019-eular.1817

Zobrazit plný text záznamu

QA: Steven E. McKenzie, MD, PhD: At the Intersection of Academic Research and Biomedicine

Autor: Scott, Kober

Publikováno v: Biotechnology healthcare. 3(4)

Philadelphia's Thomas Jefferson University is making a concerted effort to take a leadership role in biomedical research. The man behind this effort - who views individualized counseling as 'cool' - hopes it will foster a team approach to undergradua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3c72622d39b934678fd0dfed61a19dbf
https://pubmed.ncbi.nlm.nih.gov/23424372

Zobrazit plný text záznamu

CMS' CAP Program: Worthy of Applause - Or Full of Flaws?

Autor: Scott, Kober

Publikováno v: Biotechnology healthcare. 3(1)

Proposed changes to the drug acquisition program haven’t quite mollified vendors and physicians who say they are left on the hook. If you’re a health plan, this bears watching.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e7ef6151deb7cf22fc43947a672f3d1d
https://pubmed.ncbi.nlm.nih.gov/23424335

Zobrazit plný text záznamu

Expect pt committees to demand more data

Autor: Scott, Kober

Publikováno v: Biotechnology healthcare. 2(3)

High-profile drug withdrawals may cause formulary committees to view biologics and other 'breakthrough' therapies more skeptically. PT members are likely to ask many more questions before approving such products.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e9032b7ef63cd08372c11d150f1a20e9
https://pubmed.ncbi.nlm.nih.gov/23393461

Zobrazit plný text záznamu

Looking at Biotech's Crystal Ball: The issues we'll be focused on in 2005

Autor: Scott, Kober

Publikováno v: Biotechnology healthcare. 2(1)

Biotech's course through 2005 will hinge on five key variables: Use of electronic medical records to speed data collectionClarifying sources of investment capitalKeeping clinicians currentReshaping benefit designs to cope with new and costly products

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f837d0af5effe771f3d6a3372f3f84af
https://pubmed.ncbi.nlm.nih.gov/23390402

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání